학술논문

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Source
In The Lancet Oncology August 2021 22(8):1126-1138
Subject
Primary Research
Articles
Language
ISSN
1470-2045